• Version
• Download 1090
• File Size 361.87 KB
• File Count 1
• Create Date January 9, 2023
• Last Updated May 21, 2024

Special Authority: Empagliflozin and Semaglutide (inj)

Pharmacare now considers SGLT2 and GLP1 (injectable) products as 2nd line diabetes drugs - after Metformin. The attached eFORMS are specific to these products.  Note that approval for a DPP4 product (a separate eFORM needed) cancels approval for either of these and vice versa.

V2_Apr24_2024 has the updated 2023 background.  The previous one is no longer accepted.  This has the signature stamp option.

There is also a version with a wet signature only, by Stan Hurwitz.   Contact Oscar Galaxy if this is the version you wish to use.

Attached Files and Latest Versions